Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach
H Norshidah, CH Leow, KE Ezleen… - Frontiers in cellular …, 2023 - frontiersin.org
An increase in the occurrence of viral infectious diseases is a global concern for human
health. According to a WHO report, dengue virus (DENV) is one of the most common viral
diseases affecting approximately 400 million people annually, with worsening symptoms in
nearly 1% of cases. Both academic and industrial researchers have conducted numerous
studies on viral epidemiology, virus structure and function, source and route of infection,
treatment targets, vaccines, and drugs. The development of CYD-TDV or Dengvaxia® …
health. According to a WHO report, dengue virus (DENV) is one of the most common viral
diseases affecting approximately 400 million people annually, with worsening symptoms in
nearly 1% of cases. Both academic and industrial researchers have conducted numerous
studies on viral epidemiology, virus structure and function, source and route of infection,
treatment targets, vaccines, and drugs. The development of CYD-TDV or Dengvaxia® …
Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach
N Harun, LC Herng, EE Kamarulzaman, HA Wahab… - 2023 - ir.unikl.edu.my
An increase in the occurrence of viral infectious diseases is a global concern for human
health. According to a WHO report, dengue virus (DENV) is one of the most common viral
diseases affecting approximately 400 million people annually, with worsening symptoms in
nearly 1% of cases. Both academic and industrial researchers have conducted numerous
studies on viral epidemiology, virus structure and function, source and route of infection,
treatment targets, vaccines, and drugs. The development of CYD-TDV or Dengvaxia® …
health. According to a WHO report, dengue virus (DENV) is one of the most common viral
diseases affecting approximately 400 million people annually, with worsening symptoms in
nearly 1% of cases. Both academic and industrial researchers have conducted numerous
studies on viral epidemiology, virus structure and function, source and route of infection,
treatment targets, vaccines, and drugs. The development of CYD-TDV or Dengvaxia® …
以上显示的是最相近的搜索结果。 查看全部搜索结果